The contributions of metabolomics in the discovery of new therapeutic targets in Alzheimer's disease.
biomarker
metabolite
metabolomic pathway
neurodegeneration
Journal
Fundamental & clinical pharmacology
ISSN: 1472-8206
Titre abrégé: Fundam Clin Pharmacol
Pays: England
ID NLM: 8710411
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
revised:
05
01
2021
received:
01
09
2020
accepted:
20
01
2021
pubmed:
24
1
2021
medline:
15
12
2021
entrez:
23
1
2021
Statut:
ppublish
Résumé
Alzheimer's disease (AD) leads to the progressive loss of memory and other cognitive functions. It is the most common form of dementia in the elderly and has become a major public health problem due to the increase in life expectancy. Although the detection of AD is based on several neuropsychological tests, imaging, and biological analyses, none of these biomarkers allows a clear understanding of the pathophysiological mechanisms involved in the disease, and no efficient treatment is currently available. Metabolomics, which allows the study of biochemical alterations underlying pathological processes, could help to identify these mechanisms, to discover new therapeutic targets, and to monitor the therapeutic response and disease progression. In this review, we have summarized and analyzed the results from a number of studies on metabolomics analyses performed in biological samples originated from the central nervous system, in AD subjects, and in animal models of this disease. This synthesis revealed modified expression of specific metabolites in pathological conditions which allowed the identification of significantly impacted metabolic pathways both in animals and humans, such as the arginine biosynthesis and the alanine, aspartate, and glutamate metabolism. We discuss the potential biochemical mechanisms involved, the extent to which they could impact the specific hallmarks of AD, and the therapeutic approaches which could be proposed as a result.
Substances chimiques
Biomarkers
0
Aspartic Acid
30KYC7MIAI
Glutamic Acid
3KX376GY7L
Arginine
94ZLA3W45F
Alanine
OF5P57N2ZX
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
582-594Informations de copyright
© 2021 Société Française de Pharmacologie et de Thérapeutique.
Références
Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol. 2018;25:59-70.
Chiffres-clés. Institut du Cerveau, https://icm-institute.org/fr/chiffres-cles/ 2020 accessed 20 July 2020).
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc. 1992;40:922-935.
McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939.
Jack CR, Bennett DA, Blennow K et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement J Alzheimers Assoc. 2018;14:535-562.
Fagan AM, Roe CM, Xiong C et al. Cerebrospinal fluid tau/β-Amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343-349.
Shaw LM, Vanderstichele H, Knapik-Czajka M et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403-413.
Li G, Sokal I, Quinn JF et al. CSF tau/A 42 ratio for increased risk of mild cognitive impairment: A follow-up study. Neurology. 2007;69:631-639.
Mattsson N, Zetterberg H, Hansson O et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302:385-393.
Visser PJ, Verhey F, Knol DL et al. Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009;8:619-627.
Klunk WE, Engler H, Nordberg A et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306-319.
Rowe CC, Ellis KA, Rimajova M et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275-1283.
Villemagne VL, Klunk WE, Mathis CA et al. Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2012;39:209-219.
Mattsson-Carlgren N, Leuzy A, Janelidze S et al. The implications of different approaches to define AT(N) in Alzheimer disease. Neurology. 2020;94:e2233-e2244.
Jagust WJ, Bandy D, Chen K et al. The ADNI PET core. Alzheimers Dement J Alzheimers Assoc. 2010;6:221-229.
Dickerson BC, Wolk DA. MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology. 2012;78:84-90.
Vemuri P, Wiste HJ, Weigand SD et al. MRI and CSF biomarkers in normal, MCI, and AD subjects. Neurology. 2009;73:287-293.
Desikan RS, Cabral HJ, Fischl B et al. Temporoparietal MRI measures of atrophy in subjects with mild cognitive impairment that predict subsequent diagnosis of Alzheimer’s disease. AJNR Am J Neuroradiol. 2009;30:532-538.
DeCarli C, Frisoni GB, Clark CM et al. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol. 2007;64:108-115.
Fleisher AS, Houston WS, Eyler LT et al. Identification of Alzheimer disease risk by functional magnetic resonance imaging. Arch Neurol. 2005;62:1881.
Fagan AM, Head D, Shah AR et al. Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65:176-183.
Hansson O, Zetterberg H, Buchhave P et al. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5:228-234.
Tapiola T, Alafuzoff I, Herukka S-K et al. Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66:382-389.
Welge V, Fiege O, Lewczuk P et al. Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease. J Neural Transm. 2009;116:203-212.
Wiltfang J, Esselmann H, Bibl M et al. Amyloid β peptide ratio 42/40 but not Aβ42 correlates with phospho-Tau in patients with low- and high-CSF Aβ40 load. J Neurochem. 2007;101:1053-1059.
McKhann GM, Knopman DS, Chertkow H et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263-269.
McKeith IG, Dickson DW, Lowe J et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863-1872.
Román GC, Tatemichi TK, Erkinjuntti T et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250-260.
Rascovsky K, Hodges JR, Kipps CM et al. Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): current limitations and future directions. Alzheimer Dis Assoc Disord. 2007;21:S14-18.
Neary D, Snowden JS, Gustafson L et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546-1554.
McKhann GM, Albert MS, Grossman M et al. Clinical and pathological diagnosis of frontotemporal dementia: report of the work group on frontotemporal dementia and Pick’s disease. Arch Neurol. 2001;58:1803-1809.
Osorio C, Kanukuntla T, Diaz E et al. The post-amyloid era in Alzheimer’s disease: trust your gut feeling. Front Aging Neurosci. 2019;11:143.
Joe E, Ringman JM. Cognitive symptoms of Alzheimer’s disease: clinical management and prevention. BMJ. 2019;367:l6217.
Zott B, Simon MM, Hong W et al. A vicious cycle of β amyloid-dependent neuronal hyperactivation. Science. 2019;365:559-565.
Hillen H. The beta amyloid dysfunction (BAD) hypothesis for Alzheimer’s disease. Front Neurosci. 2019;13:1154.
Herrup K. The case for rejecting the amyloid cascade hypothesis. Nat Neurosci. 2015;18:794-799.
Xu J, Begley P, Church SJ et al. Graded perturbations of metabolism in multiple regions of human brain in Alzheimer’s disease: Snapshot of a pervasive metabolic disorder. Biochim Biophys Acta. 2016;1862:1084-1092.
Liu P, Fleete MS, Jing Y et al. Altered arginine metabolism in Alzheimer’s disease brains. Neurobiol Aging. 2014;35:1992-2003.
Inoue K, Tsutsui H, Akatsu H et al. Metabolic profiling of Alzheimer’s disease brains. Sci Rep. 2013;3:2364.
Morrison LD, Smith DD, Kish SJ. Brain S-adenosylmethionine levels are severely decreased in Alzheimer’s disease. J Neurochem. 1996;67:1328-1331.
Lindon JC, Holmes E, Bollard ME et al. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers. 2004;9:1-31.
Trushina E, Mielke MM. Recent advances in the application of metabolomics to Alzheimer’s disease. Biochim Biophys Acta. 2014;1842:1232-1239.
González-Domínguez R, García-Barrera T, Vitorica J et al. Region-specific metabolic alterations in the brain of the APP/PS1 transgenic mice of Alzheimer’s disease. Biochim Biophys Acta BBA Mol Basis Dis. 2014;1842:2395-2402.
Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine. 2009;6:e1000097.
Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine. 2009;6:e1000100.
Tondo M, Wasek B, Escola-Gil JC et al. Altered brain metabolome is associated with memory impairment in the rTg4510 mouse model of tauopathy. Metabolites. 2020;10:69.
Bergin D, Jing Y, Mockett B et al. Altered plasma arginine metabolome precedes behavioural and brain arginine metabolomic profile changes in the APPswe/PS1ΔE9 mouse model of Alzheimer’s disease. Transl Psychiatry. 2018;8:108.
Pan X, Nasaruddin MB, Elliott CT et al. Alzheimer’s disease-like pathology has transient effects on the brain and blood metabolome. Neurobiol Aging. 2016;38:151-163.
Hunsberger HC, Greenwood BP, Tolstikov V et al. Divergence in the metabolome between natural aging and Alzheimer’s disease. Sci Rep. 2020;10:12171.
Hu Z-P, Browne ER, Liu T et al. Metabonomic profiling of TASTPM transgenic Alzheimer’s disease mouse model. J Proteome Res. 2012;11:5903-5913.
Zheng H, Zhou Q, Du Y et al. The hypothalamus as the primary brain region of metabolic abnormalities in APP/PS1 transgenic mouse model of Alzheimer’s disease. Biochim Biophys Acta BBA Mol Basis Dis. 2018;1864:263-273.
Pan X, Elliott CT, McGuinness B et al. Metabolomic profiling of bile acids in clinical and experimental samples of Alzheimer’s disease. Metabolites. 2017;7:28.
Snowden SG, Ebshiana AA, Hye A et al. Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: A nontargeted metabolomic study. PLoS Medicine. 2017;14:e1002266.
Varma VR, Oommen AM, Varma S et al. Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. PLoS Medicine. 2018;15:e1002482.
Xu J, Patassini S, Begley P et al. Cerebral deficiency of vitamin B5 (d-pantothenic acid; pantothenate) as a potentially-reversible cause of neurodegeneration and dementia in sporadic Alzheimer’s disease. Biochem Biophys Res Commun. 2020;527:676-681.
Mahajan UV, Varma VR, Griswold ME et al. Dysregulation of multiple metabolic networks related to brain transmethylation and polyamine pathways in Alzheimer disease: A targeted metabolomic and transcriptomic study. PLoS Medicine. 2020;17:e1003012.
Kim YH, Shim HS, Kim KH et al. Metabolomic analysis identifies alterations of amino acid metabolome signatures in the postmortem brain of Alzheimer’s disease. Exp Neurobiol. 2019;28:376-389.
Paglia G, Stocchero M, Cacciatore S et al. An unbiased metabolomic investigation of the Alzheimer’s disease brain points to a dysregulation of the mitochondrial aspartate metabolism. J Proteome Res. 2016;15:608-618.
Kaddurah-Daouk R, Zhu H, Sharma S et al. Alterations in metabolic pathways and networks in Alzheimer’s disease. Transl Psychiatry. 2013;3:e244.
Hao L, Wang J, Page D et al. Comparative evaluation of MS-based metabolomics software and its application to preclinical Alzheimer’s disease. Sci Rep. 2018;8:9291.
Niedzwiecki MM, Walker DI, Howell JC et al. High-resolution metabolomic profiling of Alzheimer’s disease in plasma. Ann Clin Transl Neurol. 2019;7:36-45.
Kaddurah-Daouk R, Rozen S, Matson W et al. Metabolomic changes in autopsy confirmed Alzheimer’s disease. Alzheimers Dement J Alzheimers Assoc. 2011;7:309-317.
Ratner S. Enzymes of arginine and urea synthesis. Adv Enzymol Relat Areas Mol Biol. 1973;39:1-90.
Wu G, Morris SM. Arginine metabolism: nitric oxide and beyond. Biochem J. 1998;336:1-17.
Piletz JE, Aricioglu F, Cheng J-T et al. Agmatine: clinical applications after 100 years in translation. Drug Discov Today. 2013;18:880-893.
Satriano J. Arginine pathways and the inflammatory response: interregulation of nitric oxide and polyamines: review article. Amino Acids. 2004;26:321-329.
Feil R, Kleppisch T. NO/cGMP-dependent modulation of synaptic transmission. Handb Exp Pharmacol. 2008;184:529-560.
Susswein AJ, Katzoff A, Miller N et al. Nitric oxide and memory. Neurosci Rev J Bringing Neurobiol Neurol Psychiatry. 2004;10:153-162.
Zhou L, Zhu D-Y. Neuronal nitric oxide synthase: Structure, subcellular ocalization, regulation, and clinical implications. Nitric Oxide. 2009;20:223-230.
Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012;33:829-837.
Jeynes B, Provias J. Significant negative correlations between capillary expressed eNOS and Alzheimer lesion burden. Neurosci Lett. 2009;463:244-248.
Austin SA, Santhanam AV, Katusic ZS. Endothelial nitric oxide modulates expression and processing of amyloid precursor protein. Circ Res. 2010;107:1498-1502.
Graham SF, Chevallier OP, Elliott CT et al. Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer’s disease. PLoS One. 2015;10:e0119452.
Lin C, Huang C, Huang K et al. A metabolomic approach to identifying biomarkers in blood of Alzheimer’s disease. Ann Clin Transl Neurol. 2019;6:537-545.
Gueli MC, Taibi G. Alzheimer’s disease: amino acid levels and brain metabolic status. Neurol Sci. 2013;34:1575-1579.
Ibáñez C, Simó C, Martín-Álvarez PJ et al. Toward a predictive model of Alzheimer’s disease progression using capillary electrophoresis-mass spectrometry metabolomics. Anal Chem. 2012;84:8532-8540.
Fonteh AN, Harrington RJ, Tsai A et al. Free amino acid and dipeptide changes in the body fluids from Alzheimer’s disease subjects. Amino Acids. 2007;32:213-224.
Barbul A, Lazarou SA, Efron DT et al. Arginine enhances wound healing and lymphocyte immune responses in humans. Surgery. 1990;108:331-336; discussion 336-337.
Hurson M, Regan MC, Kirk SJ et al. Metabolic effects of arginine in a healthy elderly population. J Parenter Enter Nutr. 1995;19:227-230.
Ohtsuka Y, Nakaya J. Effect of oral administration of L-arginine on senile dementia. Am J Med. 2000;108:439.
Mielke MM, Vemuri P, Rocca WA. Clinical epidemiology of Alzheimer’s disease: assessing sex and gender differences. Clin Epidemiol. 2014;6:37-48.
Fonar G, Polis B, Meirson T et al. Intracerebroventricular administration of L-arginine improves spatial memory acquisition in triple transgenic mice via reduction of oxidative stress and apoptosis. Transl Neurosci. 2018;9:43-53.
Polis B, Samson AO. Arginase as a potential target in the treatment of Alzheimer’s disease. Adv Alzheimers Dis. 2018;7:119-140.
Polis B, Srikanth KD, Gurevich V et al. Arginase inhibition supports survival and differentiation of neuronal precursors in adult Alzheimer’s disease mice. Int J Mol Sci. 2020;21:1133.
Polis B, Srikanth KD, Elliott E et al. L-norvaline reverses cognitive decline and synaptic loss in a murine model of Alzheimer’s disease. Neurotherapeutics. 2018;15:1036-1054.
D’Aniello A, Vetere A, Fisher GH et al. Presence of d-alanine in proteins of normal and Alzheimer human brain. Brain Res. 1992;592:44-48.
Fisher GH, D’Aniello A, Vetere A et al. Free D-aspartate and D-alanine in normal and Alzheimer brain. Brain Res Bull. 1991;26:983-985.
Findley CA, Bartke A, Hascup KN et al. Amyloid beta-related alterations to glutamate signaling dynamics during Alzheimer’s disease progression. ASN NEURO. 2019;11:1759091419855541.
Danysz W, Parsons CG. Alzheimer’s disease, β-amyloid, glutamate, NMDA receptors and memantine - searching for the connections. Br J Pharmacol. 2012;167:324-352.
Zimmer ER, Kalinine E, Haas CB et al. Pretreatment with memantine prevents Alzheimer-like alterations induced by intrahippocampal okadaic acid administration in rats. Curr Alzheimer Res. 2012;9:1182-1190.
Revett TJ, Baker GB, Jhamandas J et al. Glutamate system, amyloid β peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology. J Psychiatry Neurosci. 2013;38:6-23.